Found 10 matching trials
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age PHASE3 The purpose of this study is to evaluate the immunogenicity, safety, and re...
Show More Location
Pinnacle Research Group-409 E 10th St
Learn More & Join Trial
Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine PHASE2 The main purpose of this Phase II study was to assess the safety and immuno...
Show More Location
Investigational Site Number :8400003
Learn More & Join Trial
Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older PHASE1 The primary objectives of the study are:
* To describe the safety profile ...
Show More Location
Investigational Site Number :8400003
Learn More & Join Trial
Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older PHASE2 The primary objectives of the study are:
To assess the safety profile of t...
Show More Location
Synexus - Clinical Research Advantage, Inc. Site Number : 8400270
Treatments Being Tested
SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1 SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2 SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3 SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1 SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2 SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3 SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4 SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03 Learn More & Join Trial
A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults PHASE3 This study will compare the safety and tolerability of lyophilized BNT162b2...
Show More Location
Anaheim Clinical Trials, LLC
Learn More & Join Trial
mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs PHASE3 Primary#Objectives #Immunogenicity:To demonstrate the non-inferiority of bi...
Show More Location
Savannakhét Provincial hospital
Learn More & Join Trial
Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients N/A This study is a non-randomized observation and comparison of immune respons...
Show More Location
Shoklo Malaria Research Unit (SMRU)
Learn More & Join Trial
A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19 PHASE3 The purpose of this study is to learn about the safety, tolerability, and i...
Show More Location
Stanford University Medical Center CTRU - 800 Welch Road
Learn More & Join Trial
A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2 PHASE2 Primary Immunogenicity Objective:Cohort 1: GMTs of SARS-CoV-2 Omicron and r...
Show More Location
Multiple Locations
Learn More & Join Trial
A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults. PHASE1 The purpose of this research study is to evaluate the safety of and the bod...
Show More Location
Momentum Clinical Research Darlinghurst
Learn More & Join Trial